Scilex Holding Company announced an upcoming presentation of post-hoc analysis of the C.L.E.A.R. trial for SP-102 (SEMDEXA™). The presentation will occur at the 27th Annual Meeting of the American Society of Interventional Pain Physicians (ASIPP) from May 15-17, 2025.
The analysis will interpret the clinical meaningfulness of the safety and efficacy of SP-102 for the treatment of lumbosacral radicular pain (LRP). This is a significant step in communicating the potential benefits of this pipeline candidate.
The poster will be displayed throughout the meeting and published in the Pain Physician journal, making the findings accessible to a broader medical community.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.